Johnson & Johnson raised its growth ambitions, forecasting 6.5% adjusted operational sales growth and 7.3% adjusted EPS growth in 2026, with revenue expected to surpass $100 billion for the first time. The company anticipates further improvement in 2027 and aims for double-digit growth by the end of the decade, despite facing biosimilar competition for its drug STELARA. Executives plan to detail the long-term growth strategy, including new product launches and pipeline programs, at an enterprise review in December.